Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

IMMX

Live52w high -14.4%

Annual Quarterly

Core line items from IMMX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Annual Quarterly

Entity: IMMIX BIOPHARMA, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-06	Annual 2022 2022-12-08
Revenue	$0.00	$20.00M
Operating Income	Not available	Not available
Net Income	Not available	Not available
EPS (Diluted)	$-0.21	Not available
Total Assets	Not available	Not available
Total Liabilities	Not available	Not available
Cash & Equivalents	Not available	Not available
Free Cash Flow OCF − CapEx	Not available	Not available
Shares Outstanding	Not available	Not available

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from IMMX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -14.4%

Entity: IMMIX BIOPHARMA, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-06	Annual 2022 2022-12-08
Revenue	$0.00	$20.00M
Operating Income	Not available	Not available
Net Income	Not available	Not available
EPS (Diluted)	$-0.21	Not available
Total Assets	Not available	Not available
Total Liabilities	Not available	Not available
Cash & Equivalents	Not available	Not available
Free Cash Flow OCF − CapEx	Not available	Not available
Shares Outstanding	Not available	Not available

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.